Drug Insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options
- 1 September 2005
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 2 (9) , 465-474
Abstract
In Europe, the use of interventional cardiology, including percutaneous coronary intervention (PCI), is increasing rapidly. The use of anticoagulation agents in PCI procedures is essential, but despite technical improvements, a significant associated bleeding risk still exists: more than 5% of patients are estimated to require transfusion, and around a further 13% experience minor bleeding. The methods used to detect and measure blood loss following PCI, however, vary widely between institutions and clinical trials. The risk of bleeding is influenced by therapeutic options and patient-specific characteristics, such as age, anemia and previous exposure to anticoagulants. Bleeding is associated with death, and also with less severe conditions such as thrombocytopenia, anemia, and hematoma, which have major impacts on patients' welfare and length of hospital stay, and on hospital budgets. Unfractionated heparin is the most widely used anticoagulant during PCI. Heparin, antiplatelet agents and other anticoagulants, however, have limitations that make it difficult to achieve a level of anticoagulation that prevents ischemic events without promoting bleeding. The use of low-molecular-weight heparin and the addition of glycoprotein IIb/IIIa inhibitors offer improved outcomes, but safer and more effective therapeutic agents are still required. New anticoagulants, including direct thrombin inhibitors such as bivalirudin, show similar levels of efficacy to heparin plus glycoprotein IIb/IIIa inhibitors, but with fewer hemorrhagic complications, and might advance clinical practice. This review evaluates the impact of PCI-related bleeding on patients' outcomes and hospital resources, examines methods for the detection and measurement of bleeding, and appraises the therapeutic options—particularly the newer agents—available to minimize hemorrhagic complications.Keywords
This publication has 48 references indexed in Scilit:
- The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trialAmerican Heart Journal, 2005
- Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)The American Journal of Cardiology, 2005
- Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registryHeart, 2005
- Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta-analysis of randomized, controlled trialsAmerican Heart Journal, 2004
- Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study)The American Journal of Cardiology, 2004
- Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationaleAmerican Heart Journal, 2004
- Bivalirudin in PCI: An Overview of the REPLACE-2 TrialSeminars in Thrombosis and Hemostasis, 2004
- P2Y12, A New Platelet ADP Receptor, Target of ClopidogrelSeminars in Vascular Medicine, 2003
- Patterns of use of heparins in ACSThrombosis and Haemostasis, 2003
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995